Why This Module Matters for Your Practice

Acute mania is the defining clinical emergency of bipolar I disorder, and the treatment decisions made in the first days of a manic episode shape the patient's trajectory for months or years to come. The pharmacotherapy of acute mania has evolved substantially over the past two decades. Network meta-analyses involving tens of thousands of patients have clarified which agents work best and how quickly, and have established that combination therapy outperforms monotherapy for severe presentations. Lithium, the oldest psychiatric medication still in routine use, has accumulated an evidence base that no other mood stabilizer can match for long-term relapse prevention and suicide risk reduction, yet newer agents have increasingly displaced lithium in clinical practice, carrying their own serious long-term consequences. Meanwhile, regulatory restrictions on valproate in patients under 55 are reshaping prescribing patterns globally, and the atypical antipsychotics that increasingly fill the gap carry metabolic risks that demand proactive monitoring across every clinical setting.

This module equips you with the evidence and clinical reasoning to navigate these decisions confidently. The practical tools here apply whether you are a prescriber initiating treatment in an emergency department, a PCP managing a stable patient, or a therapist supporting medication adherence.

After completing this module, you will be able to:

Apply a severity-based treatment algorithm for acute mania, selecting between monotherapy and combination therapy based on episode severity, psychotic features, and patient-specific risk factors.
Prescribe and monitor lithium using current evidence-based protocols, including therapeutic levels by illness phase, the monitoring schedule, high-risk drug interactions, and toxicity recognition, and articulate the evidence for lithium's unique anti-suicidal properties.
Evaluate valproate, carbamazepine, and lamotrigine for their specific clinical niches in bipolar disorder, including valproate's role in mixed features and rapid cycling, the current reproductive safety restrictions, and the critical distinction that lamotrigine lacks antimanic efficacy.
Compare the atypical antipsychotics used in acute mania on efficacy, metabolic risk, and neuromotor side effects, and implement the ADA/APA metabolic monitoring protocol for any patient on long-term antipsychotic therapy.

Clinical Pearl: Cross-Module Connection

This module builds on the diagnostic framework established in Module 2 (Evaluation and Diagnosis), which addressed why bipolar disorder is so difficult to diagnose, the bipolar-unipolar boundary, and the clinical features that raise suspicion for bipolar in a patient presenting with depression. With the diagnosis established, this module turns to the treatment question: a manic episode requires treatment, and the pharmacotherapy decisions are complex. The pharmacotherapy of bipolar depression and maintenance treatment follows in Module 4, while psychotherapy as an adjunct to pharmacotherapy is the focus of Module 5. Cross-references to the Depression series (particularly regarding antidepressant-induced mood switching) and the ADHD series (regarding stimulant use in comorbid populations) are noted where relevant.

Section 1: Acute Mania Treatment: What the Guidelines Recommend

1.1 The Clinical Problem: Why Acute Mania Demands Rapid, Structured Intervention

A manic episode is not simply an elevated mood that will resolve on its own. The clinical objectives during acute mania extend beyond symptom control to include preventing the psychosocial damage that accumulates rapidly during untreated episodes (financial ruin, relationship destruction, occupational loss, legal consequences) and, increasingly recognized, preventing the potential neurotoxic effects of recurrent episodes on brain structure and cognitive function (Berk et al., 2017, World Psychiatry, 16, 236-244). Acute mania also carries significant suicide risk, particularly during mixed episodes where manic energy combines with depressive despair (Marzani & Neff, 2021, American Family Physician, 103(4), 227-239).

The treatment goals are straightforward in principle: rapidly attenuate dangerous behaviors, restore sleep, resolve psychotic symptoms if present, and initiate a medication regimen that will serve the patient in the long term. In practice, these goals require navigating a complex landscape of medication choices, each with distinct timelines to efficacy, side effect profiles, and implications for maintenance treatment.

PsychHQ

Introduction & Acute Mania Clinical Challenge